Jazz Pharmaceuticals plc (JAZZ)
USD 102.82
(-3.84%)
USD 102.82
(-3.84%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 414.83 Million USD | 293.72% |
| 2022 | -214.13 Million USD | 34.9% |
| 2021 | -328.95 Million USD | -237.86% |
| 2020 | 238.61 Million USD | -54.41% |
| 2019 | 523.36 Million USD | 17.06% |
| 2018 | 447.09 Million USD | -8.35% |
| 2017 | 487.84 Million USD | 22.94% |
| 2016 | 396.83 Million USD | 20.42% |
| 2015 | 329.53 Million USD | 464.4% |
| 2014 | 58.38 Million USD | -73.01% |
| 2013 | 216.31 Million USD | -25.04% |
| 2012 | 288.58 Million USD | 130.9% |
| 2011 | 124.98 Million USD | 281.3% |
| 2010 | 32.77 Million USD | 579.49% |
| 2009 | -6.83 Million USD | 96.29% |
| 2008 | -184.33 Million USD | -32.78% |
| 2007 | -138.82 Million USD | -133.75% |
| 2006 | -59.39 Million USD | 30.26% |
| 2005 | -85.15 Million USD | -243.32% |
| 2004 | -24.8 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -14.61 Million USD | -115.53% |
| 2024 Q2 | 168.56 Million USD | 1253.15% |
| 2023 Q2 | 104.43 Million USD | 50.44% |
| 2023 FY | 414.83 Million USD | 293.72% |
| 2023 Q4 | 94.15 Million USD | -35.87% |
| 2023 Q3 | 146.82 Million USD | 40.58% |
| 2023 Q1 | 69.42 Million USD | 128.93% |
| 2022 Q2 | 34.66 Million USD | 498.81% |
| 2022 Q1 | 5.78 Million USD | 116.38% |
| 2022 FY | -214.13 Million USD | 34.9% |
| 2022 Q4 | -239.95 Million USD | -1302.98% |
| 2022 Q3 | -17.1 Million USD | -149.34% |
| 2021 Q3 | -52.83 Million USD | 85.46% |
| 2021 Q1 | 121.83 Million USD | -8.68% |
| 2021 Q2 | -363.31 Million USD | -398.21% |
| 2021 Q4 | -35.35 Million USD | 33.09% |
| 2021 FY | -328.95 Million USD | -237.86% |
| 2020 Q3 | 148.23 Million USD | 29.12% |
| 2020 FY | 238.61 Million USD | -54.41% |
| 2020 Q4 | 133.41 Million USD | -10.0% |
| 2020 Q1 | -157.83 Million USD | -313.31% |
| 2020 Q2 | 114.8 Million USD | 172.74% |
| 2019 FY | 523.36 Million USD | 17.06% |
| 2019 Q2 | 261.89 Million USD | 207.39% |
| 2019 Q3 | 102.27 Million USD | -60.95% |
| 2019 Q4 | 73.99 Million USD | -27.65% |
| 2019 Q1 | 85.2 Million USD | -46.57% |
| 2018 FY | 447.09 Million USD | -8.35% |
| 2018 Q4 | 159.47 Million USD | 6.8% |
| 2018 Q3 | 149.31 Million USD | 61.74% |
| 2018 Q2 | 92.32 Million USD | 100.74% |
| 2018 Q1 | 45.99 Million USD | -80.19% |
| 2017 Q1 | 86.51 Million USD | -25.86% |
| 2017 FY | 487.84 Million USD | 22.94% |
| 2017 Q4 | 232.2 Million USD | 265.53% |
| 2017 Q3 | 63.52 Million USD | -39.85% |
| 2017 Q2 | 105.6 Million USD | 22.07% |
| 2016 FY | 396.83 Million USD | 20.42% |
| 2016 Q1 | 74.12 Million USD | -10.44% |
| 2016 Q4 | 116.68 Million USD | 33.9% |
| 2016 Q3 | 87.14 Million USD | -21.69% |
| 2016 Q2 | 111.28 Million USD | 50.14% |
| 2015 Q3 | 87.96 Million USD | -0.17% |
| 2015 FY | 329.53 Million USD | 464.4% |
| 2015 Q1 | 70.7 Million USD | -13.37% |
| 2015 Q2 | 88.11 Million USD | 24.63% |
| 2015 Q4 | 82.76 Million USD | -5.91% |
| 2014 Q2 | 43.65 Million USD | 147.12% |
| 2014 FY | 58.38 Million USD | -73.01% |
| 2014 Q1 | -92.65 Million USD | -267.56% |
| 2014 Q4 | 81.61 Million USD | 216.74% |
| 2014 Q3 | 25.76 Million USD | -40.98% |
| 2013 Q4 | 55.29 Million USD | -26.68% |
| 2013 FY | 216.31 Million USD | -25.04% |
| 2013 Q2 | 42.18 Million USD | -2.86% |
| 2013 Q1 | 43.42 Million USD | -78.35% |
| 2013 Q3 | 75.4 Million USD | 78.76% |
| 2012 Q2 | 27.14 Million USD | -1.94% |
| 2012 FY | 288.58 Million USD | 130.9% |
| 2012 Q1 | 27.68 Million USD | -26.13% |
| 2012 Q4 | 200.55 Million USD | 503.91% |
| 2012 Q3 | 33.2 Million USD | 22.34% |
| 2011 Q1 | 21.82 Million USD | -10.76% |
| 2011 Q2 | 33.2 Million USD | 52.11% |
| 2011 Q3 | 32.48 Million USD | -2.17% |
| 2011 Q4 | 37.47 Million USD | 15.37% |
| 2011 FY | 124.98 Million USD | 281.3% |
| 2010 FY | 32.77 Million USD | 579.49% |
| 2010 Q2 | -6.38 Million USD | -536.34% |
| 2010 Q1 | 1.46 Million USD | -74.1% |
| 2010 Q4 | 24.45 Million USD | 84.69% |
| 2010 Q3 | 13.24 Million USD | 307.31% |
| 2009 Q3 | -1.67 Million USD | -177.02% |
| 2009 Q4 | 5.65 Million USD | 438.1% |
| 2009 FY | -6.83 Million USD | 96.29% |
| 2009 Q2 | 2.17 Million USD | 116.72% |
| 2009 Q1 | -12.98 Million USD | 77.19% |
| 2008 Q3 | -28.8 Million USD | 44.47% |
| 2008 Q4 | -56.94 Million USD | -97.65% |
| 2008 Q1 | -46.71 Million USD | 22.18% |
| 2008 Q2 | -51.88 Million USD | -11.07% |
| 2008 FY | -184.33 Million USD | -32.78% |
| 2007 Q1 | -19.58 Million USD | -58.74% |
| 2007 Q4 | -60.02 Million USD | -210.04% |
| 2007 Q2 | -39.86 Million USD | -103.55% |
| 2007 Q3 | -19.35 Million USD | 51.44% |
| 2007 FY | -138.82 Million USD | -133.75% |
| 2006 Q4 | -12.33 Million USD | 0.0% |
| 2006 FY | -59.39 Million USD | 30.26% |
| 2006 Q1 | -22.37 Million USD | -5.12% |
| 2006 Q2 | -12.33 Million USD | 44.87% |
| 2006 Q3 | -12.33 Million USD | 0.0% |
| 2005 Q4 | -21.28 Million USD | 0.0% |
| 2005 Q2 | -21.28 Million USD | 0.0% |
| 2005 FY | -85.15 Million USD | -243.32% |
| 2005 Q1 | -21.28 Million USD | 0.0% |
| 2005 Q3 | -21.28 Million USD | 0.0% |
| 2004 FY | -24.8 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -51.92 Million USD | 898.906% |
| Jaguar Health, Inc. | -41.3 Million USD | 1104.436% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 371.146% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 862.251% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 194.228% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -695.398% |
| ContextLogic Inc. | -317 Million USD | 230.862% |
| MiMedx Group, Inc. | 67.43 Million USD | -515.122% |
| MEI Pharma, Inc. | 17.77 Million USD | -2233.401% |
| AlloVir, Inc. | -190.41 Million USD | 317.853% |
| Novavax, Inc. | -545.06 Million USD | 176.107% |
| Aptorum Group Limited | -2.82 Million USD | 14786.154% |
| Ardelyx, Inc. | -66.06 Million USD | 727.896% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 302.086% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 910.867% |
| Vaxcyte, Inc. | -402.26 Million USD | 203.124% |
| Precigen, Inc. | -95.9 Million USD | 532.549% |
| Pharming Group N.V. | -10.54 Million USD | 4032.802% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 305.778% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 1790.225% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 1753.31% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 295.473% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 2336.762% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 1804.372% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 1804.372% |
| Bicycle Therapeutics plc | -180.66 Million USD | 329.615% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 260.893% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 1622.99% |
| Acelyrin, Inc. | -381.64 Million USD | 208.697% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 1210.959% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 1316.48% |
| Senti Biosciences, Inc. | -92.91 Million USD | 546.445% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 496.214% |
| AbCellera Biologics Inc. | -146.39 Million USD | 383.359% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 1280.512% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 331.681% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 6305.415% |
| Chimerix, Inc. | -82.09 Million USD | 605.307% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 1512.819% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 2144.414% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 1030.047% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 912.472% |
| Elevation Oncology, Inc. | -45.7 Million USD | 1007.649% |
| Alkermes plc | 355.75 Million USD | -16.605% |
| Fortress Biotech, Inc. | -60.63 Million USD | 784.124% |
| Fortress Biotech, Inc. | -60.63 Million USD | 784.124% |
| Agenus Inc. | -245.76 Million USD | 268.795% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 608.497% |
| Dyadic International, Inc. | -6.79 Million USD | 6204.545% |
| ImmuCell Corporation | -5.77 Million USD | 7283.738% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 44419.658% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 467.235% |
| Lantern Pharma Inc. | -15.96 Million USD | 2698.948% |
| Immix Biopharma, Inc. | -15.42 Million USD | 2789.166% |
| Incyte Corporation | 597.59 Million USD | 30.584% |
| IO Biotech, Inc. | -86.08 Million USD | 581.898% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 811.633% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 2280.012% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 803.312% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 352.064% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 4979.802% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 665.575% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 211.027% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 172.416% |
| NextCure, Inc. | -62.72 Million USD | 761.371% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 4254.136% |
| Onconetix, Inc. | -37.4 Million USD | 1208.889% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 1150.766% |
| Opthea Limited | -220.24 Million USD | 288.353% |
| PDS Biotechnology Corporation | -42.94 Million USD | 1066.024% |
| PureTech Health plc | -65.69 Million USD | 731.432% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 662.179% |
| Seer, Inc. | -86.27 Million USD | 580.814% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 3307460.702% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 1376.996% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 3273.472% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 1558.006% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 821.284% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 766.343% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 413.097% |
| ChromaDex Corporation | -4.93 Million USD | 8500.81% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 11661.65% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 506.419% |
| CRISPR Therapeutics AG | -153.61 Million USD | 370.055% |
| Precision BioSciences, Inc. | -61.31 Million USD | 776.515% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 357.775% |
| Innoviva, Inc. | 179.72 Million USD | -130.819% |
| Summit Therapeutics Inc. | -614.92 Million USD | 167.46% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 719.198% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 730.779% |
| ESSA Pharma Inc. | -26.58 Million USD | 1660.555% |
| GlycoMimetics, Inc. | -36.89 Million USD | 1224.224% |
| GT Biopharma, Inc. | -7.59 Million USD | 5560.471% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 271.872% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -480.916% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 944.528% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 4270.11% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 268.909% |
| Aptose Biosciences Inc. | -51.2 Million USD | 910.108% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 522.015% |
| Soligenix, Inc. | -6.14 Million USD | 6855.418% |
| Century Therapeutics, Inc. | -136.67 Million USD | 403.522% |
| Kura Oncology, Inc. | -152.63 Million USD | 371.788% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 564.964% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 4036.534% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -73260.567% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 73005.448% |
| Autolus Therapeutics plc | -208.38 Million USD | 299.072% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 676.973% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 685.962% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 2014.491% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 284.165% |
| GRI Bio, Inc. | -13.03 Million USD | 3281.959% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 10133.237% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 434.315% |
| IGM Biosciences, Inc. | -246.41 Million USD | 268.346% |
| INmune Bio, Inc. | -30 Million USD | 1482.405% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 475.213% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 1083.159% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 2698.928% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 2726.353% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 795.036% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 510.047% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 250.233% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 274.378% |
| Verastem, Inc. | -87.36 Million USD | 574.815% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 865.542% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 357.123% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 455.597% |
| Histogen Inc. | -10.62 Million USD | 4005.772% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 3003.612% |
| Surrozen, Inc. | -43.04 Million USD | 1063.784% |
| Organovo Holdings, Inc. | -14.67 Million USD | 2927.565% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 8254.701% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 892.587% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 1742.054% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 1639.951% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 5063.835% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 374.569% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 947.876% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 1495.566% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 4081.991% |
| Apollomics, Inc. | -172.6 Million USD | 340.342% |
| Amarin Corporation plc | -59.11 Million USD | 801.773% |
| Mesoblast Limited | -87.95 Million USD | 571.636% |
| Turnstone Biologics Corp. | -55.2 Million USD | 851.507% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 382.272% |
| Synaptogenix, Inc. | -6.03 Million USD | 6969.781% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 2659.427% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 631.7% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 8757.726% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 5037.185% |
| Exelixis, Inc. | 207.76 Million USD | -99.664% |
| Better Therapeutics, Inc. | -39.76 Million USD | 1143.34% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 388.182% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 178.473% |
| NLS Pharmaceutics AG | -12.17 Million USD | 3508.076% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 5421.982% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 1449.091% |
| Gritstone bio, Inc. | -138.49 Million USD | 399.539% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 743.5% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 10470.93% |
| Avid Bioservices, Inc. | -140.75 Million USD | 394.723% |
| Insmed Incorporated | -749.56 Million USD | 155.343% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 2831.043% |
| MediWound Ltd. | -6.71 Million USD | 6276.772% |
| OmniAb, Inc. | -50.61 Million USD | 919.518% |
| Alector, Inc. | -130.39 Million USD | 418.145% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 464.771% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 900.108% |
| Zai Lab Limited | -334.62 Million USD | 223.971% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 228.04% |
| Aura Biosciences, Inc. | -76.4 Million USD | 642.917% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 276.801% |
| Immunic, Inc. | -93.61 Million USD | 543.14% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 405.264% |
| Veracyte, Inc. | -74.4 Million USD | 657.54% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 5504.59% |
| FibroGen, Inc. | -284.23 Million USD | 245.948% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 1681.397% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 6024.572% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 2302.723% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 1939.202% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -741.939% |
| TG Therapeutics, Inc. | 12.67 Million USD | -3173.611% |
| Galecto, Inc. | -38.34 Million USD | 1181.728% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 2298.834% |
| Fortrea Holdings Inc. | -3.4 Million USD | 12300.941% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 427.558% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 2482.586% |
| XBiotech Inc. | -24.55 Million USD | 1789.262% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 743.5% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 761.825% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 521.466% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 2036.025% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 851.603% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 168.382% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 707.768% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 728719.103% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 283.117% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 1962.947% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 288.809% |
| NexImmune, Inc. | -32.34 Million USD | 1382.547% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 7946.897% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 3053.404% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 89.507% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 1812.696% |
| Scopus BioPharma Inc. | -11.6 Million USD | 3673.111% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 455.17% |
| Ainos, Inc. | -13.77 Million USD | 3112.458% |
| Pluri Inc. | -20.88 Million USD | 2085.982% |
| Prothena Corporation plc | -147.02 Million USD | 382.145% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 464.3% |
| Celularity Inc. | -196.29 Million USD | 311.331% |
| Rallybio Corporation | -74.56 Million USD | 656.344% |
| Cue Biopharma, Inc. | -50.73 Million USD | 917.677% |
| MeiraGTx Holdings plc | -84.02 Million USD | 593.689% |
| Omeros Corporation | -117.81 Million USD | 452.111% |
| Humacyte, Inc. | -110.77 Million USD | 474.478% |
| Immunocore Holdings plc | -55.28 Million USD | 850.325% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 2406.673% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 1909.045% |
| Blueprint Medicines Corporation | -506.98 Million USD | 181.823% |
| CalciMedica, Inc. | -34.35 Million USD | 1307.416% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 712.977% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 393.364% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 350.217% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 246.452% |
| Pulmatrix, Inc. | -14.12 Million USD | 3037.696% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 1278.667% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 601.987% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 186.209% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 495.564% |
| Cytokinetics, Incorporated | -526.24 Million USD | 178.829% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 1250.234% |
| Nutriband Inc. | -5.48 Million USD | 7662.593% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 1126.304% |
| Vor Biopharma Inc. | -117.86 Million USD | 451.961% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 90.461% |
| Evogene Ltd. | -23.87 Million USD | 1837.225% |
| ProKidney Corp. | -35.46 Million USD | 1269.595% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 446.377% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 5387.589% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 164.495% |
| CorMedix Inc. | -46.33 Million USD | 995.207% |
| BioLineRx Ltd. | -60.61 Million USD | 784.383% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 507.721% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 1110.159% |
| Atai Life Sciences N.V. | -40.22 Million USD | 1131.305% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 614.36% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 649.294% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 241.973% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 1588.133% |
| MediciNova, Inc. | -8.57 Million USD | 4939.657% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 436.504% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 5052.133% |
| GeoVax Labs, Inc. | -25.96 Million USD | 1697.55% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 273.397% |
| Biomea Fusion, Inc. | -117.25 Million USD | 453.786% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 166.203% |
| Mereo BioPharma Group plc | -29.46 Million USD | 1507.833% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 370.845% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 298.143% |
| Absci Corporation | -110.56 Million USD | 475.189% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 1475.894% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 511.389% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 275.823% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -2845.413% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 314.981% |
| Allakos Inc. | -185.7 Million USD | 323.387% |
| Imunon, Inc. | -19.51 Million USD | 2225.711% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 526.19% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -290.835% |
| BioAtla, Inc. | -123.46 Million USD | 436.0% |
| NLS Pharmaceutics AG | -12.17 Million USD | 3508.076% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 2680.122% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 226.757% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 1222.715% |
| XOMA Corporation | -40.83 Million USD | 1115.973% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 507.217% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 450.031% |
| aTyr Pharma, Inc. | -50.38 Million USD | 923.259% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 573.126% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 373.349% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 274.494% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 1281.218% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 5226.484% |
| Akari Therapeutics, Plc | -10 Million USD | 4245.004% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 616263.387% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -47.316% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 6324.13% |
| UroGen Pharma Ltd. | -102.24 Million USD | 505.727% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 488.445% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 5433.961% |
| Orgenesis Inc. | -55.36 Million USD | 849.322% |
| Entera Bio Ltd. | -8.88 Million USD | 4766.802% |
| GH Research PLC | -35.58 Million USD | 1265.684% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 2090.557% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 636.042% |
| Xencor, Inc. | -126.08 Million USD | 429.005% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 11116.06% |
| Replimune Group, Inc. | -215.79 Million USD | 292.235% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 2050.633% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -16433.758% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 6324.13% |
| Portage Biotech Inc. | -75.33 Million USD | 650.621% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 5052.133% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 529.188% |
| OncoCyte Corporation | -27.78 Million USD | 1593.222% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 3191.79% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 3829.994% |
| Purple Biotech Ltd. | -19.88 Million USD | 2186.68% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 6010.13% |
| scPharmaceuticals Inc. | -54.81 Million USD | 856.855% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 2469.637% |
| HilleVax, Inc. | -123.56 Million USD | 435.717% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 4204.403% |
| Tharimmune, Inc. | -9.31 Million USD | 4551.42% |
| Genprex, Inc. | -30.86 Million USD | 1444.218% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 275.832% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 1478.454% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 23379.012% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 7932.908% |
| OKYO Pharma Limited | -16.82 Thousand USD | 2465601.686% |
| Savara Inc. | -54.69 Million USD | 858.404% |
| Curis, Inc. | -47.41 Million USD | 974.933% |
| Daré Bioscience, Inc. | -30.16 Million USD | 1475.374% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 2785.851% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 7548.95% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 1491.353% |
| BeiGene, Ltd. | -881.7 Million USD | 147.049% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 2048.117% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 195.065% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 625.403% |
| Erasca, Inc. | -125.04 Million USD | 431.754% |
| bluebird bio, Inc. | -211.91 Million USD | 295.756% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 8395.815% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -147.447% |
| DBV Technologies S.A. | -72.72 Million USD | 670.404% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 8395.815% |
| Moderna, Inc. | -4.71 Billion USD | 108.8% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 1133.025% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 7385.423% |
| Molecular Templates, Inc. | -8.12 Million USD | 5206.253% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 786.944% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 472.384% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 406.484% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 965.694% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 393.315% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 315.598% |
| MacroGenics, Inc. | -9.05 Million USD | 4679.731% |
| RenovoRx, Inc. | -10.23 Million USD | 4154.261% |
| Adicet Bio, Inc. | -142.65 Million USD | 390.788% |
| Prime Medicine, Inc. | -198.13 Million USD | 309.37% |
| Aditxt, Inc. | -32.38 Million USD | 1381.103% |
| Adagene Inc. | -18.94 Million USD | 2289.506% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 5773.519% |
| Quantum-Si incorporated | -95.96 Million USD | 532.297% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 448.513% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 2945.648% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -213.483% |
| SciSparc Ltd. | -5.12 Million USD | 8199.024% |
| Vericel Corporation | -3.18 Million USD | 13136.832% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 345063.161% |
| Minerva Neurosciences, Inc. | -30 Million USD | 1482.527% |
| Generation Bio Co. | -126.61 Million USD | 427.64% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 669.113% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 603.18% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 258.248% |
| Invivyd, Inc. | -198.64 Million USD | 308.833% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 221.305% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 4875.554% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -1718.96% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 4301.256% |
| 2seventy bio, Inc. | -217.57 Million USD | 290.666% |
| ADMA Biologics, Inc. | -28.23 Million USD | 1569.004% |
| Clene Inc. | -49.5 Million USD | 937.977% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 1961.273% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 939.163% |
| GeoVax Labs, Inc. | -25.96 Million USD | 1697.55% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 226.448% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 1374.723% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -1725.845% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 519.906% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 654.93% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 357.972% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 167.446% |
| Evaxion Biotech A/S | -22.12 Million USD | 1974.947% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 613.813% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 307.346% |
| Trevena, Inc. | -40.28 Million USD | 1129.641% |
| Surrozen, Inc. | -43.04 Million USD | 1063.784% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 700.041% |
| Cingulate Inc. | -23.53 Million USD | 1862.621% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 6101.62% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 1140.723% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 5479.971% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 559.851% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 776.879% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 797.161% |
| Clearmind Medicine Inc. | -11.95 Million USD | 3569.937% |
| Kronos Bio, Inc. | -112.67 Million USD | 468.173% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 699.494% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 16356345.293% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 582.952% |
| Statera Biopharma, Inc. | -174.4 Million USD | 337.851% |
| ImmunityBio, Inc. | -583.19 Million USD | 171.131% |
| Korro Bio, Inc. | -81.17 Million USD | 611.053% |
| Kineta, Inc. | -14.09 Million USD | 3042.28% |
| BioVie Inc. | -32.12 Million USD | 1391.485% |
| Codexis, Inc. | -76.24 Million USD | 644.113% |
| Celularity Inc. | -196.29 Million USD | 311.331% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 293.369% |
| Celcuity Inc. | -63.77 Million USD | 750.42% |
| Virax Biolabs Group Limited | -6.73 Million USD | 6260.685% |
| Cibus, Inc. | -267.62 Million USD | 255.004% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 1128.696% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 1258.393% |
| IN8bio, Inc. | -30 Million USD | 1482.451% |
| Kodiak Sciences Inc. | -260.49 Million USD | 259.25% |
| Annexon, Inc. | -134.23 Million USD | 409.03% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 454.058% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 777.52% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 1415.09% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 213.254% |
| Eyenovia, Inc. | -27.26 Million USD | 1621.7% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -1821.319% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 77638.692% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 642.945% |
| Arcellx, Inc. | -70.69 Million USD | 686.833% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 1101.018% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 410.002% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 1481.07% |
| Moolec Science SA | -51.78 Million USD | 901.006% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 892.102% |
| Geron Corporation | -184.12 Million USD | 325.297% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 1088.307% |
| Royalty Pharma plc | 1.13 Billion USD | 63.446% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 405.122% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 4765.331% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 2052.773% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 341.645% |
| Humacyte, Inc. | -110.77 Million USD | 474.478% |
| Structure Therapeutics Inc. | -89.62 Million USD | 562.879% |
| 89bio, Inc. | -142.18 Million USD | 391.747% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 701.555% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 4097.61% |
| Genelux Corporation | -28.29 Million USD | 1565.993% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 1527.256% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 334.211% |
| Notable Labs, Ltd. | -11.26 Million USD | 3782.813% |
| Liquidia Corporation | -78.5 Million USD | 628.435% |
| Mustang Bio, Inc. | -51.6 Million USD | 903.907% |
| Immunovant, Inc. | -259.33 Million USD | 259.959% |
| Quantum-Si incorporated | -95.96 Million USD | 532.297% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 669.441% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 2240.406% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 532.162% |
| Acasti Pharma Inc. | -12.85 Million USD | 3327.511% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 1947.157% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 2698.928% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 327.439% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 9743.854% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 3426.64% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 1506.639% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 1163.999% |
| PepGen Inc. | -78.62 Million USD | 627.602% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 1493.503% |
| United Therapeutics Corporation | 984.8 Million USD | 57.877% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 1963.576% |
| Solid Biosciences Inc. | -96.01 Million USD | 532.049% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 8757.726% |
| Immuneering Corporation | -53.47 Million USD | 875.798% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 8254.701% |
| Silo Pharma, Inc. | -3.7 Million USD | 11309.606% |
| Belite Bio, Inc | -31.63 Million USD | 1411.431% |
| XOMA Corporation | -40.83 Million USD | 1115.973% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 863.05% |
| Bionomics Limited | -15.49 Billion USD | 102.678% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 593.936% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 1522.753% |
| uniQure N.V. | -308.47 Million USD | 234.477% |
| Cassava Sciences, Inc. | -97.21 Million USD | 526.707% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 5773.519% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 436.087% |
| Forte Biosciences, Inc. | -31.47 Million USD | 1417.931% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 5157.876% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 1527.109% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 77638.692% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 1681.397% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 2616.421% |
| Altimmune, Inc. | -88.44 Million USD | 569.018% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 373.665% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 1522.753% |
| Compugen Ltd. | -18.75 Million USD | 2311.965% |
| Peak Bio, Inc. | -1259.26 USD | 32942621.799% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 1000.849% |
| Benitec Biopharma Inc. | -21.75 Million USD | 2007.186% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 222.445% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 600.075% |
| Zura Bio Limited | -60.36 Million USD | 787.263% |
| PolyPid Ltd. | -23.86 Million USD | 1838.244% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 2736.868% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 600.075% |
| Instil Bio, Inc. | -156.08 Million USD | 365.77% |
| argenx SE | -295.05 Million USD | 240.596% |
| Immunome, Inc. | -106.8 Million USD | 488.398% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 1076.213% |
| Verona Pharma plc | -54.36 Million USD | 862.994% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 515.177% |
| Shattuck Labs, Inc. | -87.29 Million USD | 575.191% |
| CervoMed Inc. | -2.17 Million USD | 19200.196% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 432.795% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 3215.29% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 1052.433% |
| Moolec Science SA | -51.78 Million USD | 901.006% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 2399119.647% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 407.016% |
| AnaptysBio, Inc. | -163.61 Million USD | 353.535% |
| Design Therapeutics, Inc. | -66.86 Million USD | 720.43% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 609.534% |
| NeurAxis, Inc. | -14.62 Million USD | 2936.132% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 1195.064% |
| Lumos Pharma, Inc. | -34.03 Million USD | 1318.875% |
| Achilles Therapeutics plc | -69.66 Million USD | 695.467% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 515.177% |
| 180 Life Sciences Corp. | -19.93 Million USD | 2180.911% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -13687.336% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 16356345.293% |
| Nutriband Inc. | -5.48 Million USD | 7662.593% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 511.961% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 953.441% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 638.107% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 1321.172% |
| MoonLake Immunotherapeutics | -36 Million USD | 1252.079% |
| Palisade Bio, Inc. | -12.3 Million USD | 3472.618% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 1084.788% |
| Beam Therapeutics Inc. | -132.52 Million USD | 413.017% |
| Neurogene Inc. | -36.31 Million USD | 1242.253% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 353.852% |
| AEON Biopharma, Inc. | -52.55 Million USD | 889.314% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 522.664% |
| Sesen Bio, Inc. | -19.88 Million USD | 2186.26% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 679.504% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 3414.971% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 193.423% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 471.827% |
| Athira Pharma, Inc. | -117.67 Million USD | 452.532% |
| Vaccinex, Inc. | -20.25 Million USD | 2148.452% |
| HCW Biologics Inc. | -24.99 Million USD | 1759.708% |
| XOMA Corporation | -40.83 Million USD | 1115.973% |
| Nektar Therapeutics | -276.05 Million USD | 250.271% |
| Arvinas, Inc. | -367.3 Million USD | 212.941% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 616263.387% |
| Merus N.V. | -154.93 Million USD | 367.739% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 525.783% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 1421.752% |
| Rezolute, Inc. | -68.45 Million USD | 705.957% |
| Clene Inc. | -49.5 Million USD | 937.977% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 2789.615% |
| BeyondSpring Inc. | -21.02 Million USD | 2072.948% |
| Synlogic, Inc. | -57.28 Million USD | 824.193% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 3585.69% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 3931.812% |
| Peak Bio, Inc. | -1259.26 USD | 32942621.799% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 1210.126% |
| Krystal Biotech, Inc. | 10.93 Million USD | -3694.658% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 389.892% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 227.6% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 9081.06% |
| MannKind Corporation | -11.93 Million USD | 3574.887% |
| Ikena Oncology, Inc. | -68.16 Million USD | 708.561% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 2073.98% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 546.377% |
| Gossamer Bio, Inc. | -179.81 Million USD | 330.697% |
| CohBar, Inc. | -11.96 Million USD | 3567.881% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 1708.624% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 1475.894% |
| Legend Biotech Corporation | -518.25 Million USD | 180.044% |
| Mural Oncology plc | -207.44 Million USD | 299.97% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 434.232% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 2368.115% |
| Disc Medicine, Inc. | -76.42 Million USD | 642.768% |
| Champions Oncology, Inc. | -7.27 Million USD | 5801.374% |
| REGENXBIO Inc. | -263.49 Million USD | 257.435% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 4008.688% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 973.239% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 1192.137% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 514.157% |
| Vaxart, Inc. | -82.46 Million USD | 603.04% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -124189.391% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 1204.966% |
| Cellectis S.A. | -101.05 Million USD | 510.485% |
| Longeveron Inc. | -21.41 Million USD | 2037.29% |
| Repare Therapeutics Inc. | -93.79 Million USD | 542.27% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 177.397% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 682.883% |
| Revolution Medicines, Inc. | -436.36 Million USD | 195.065% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 6413.073% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 1445.808% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 698.318% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 740.845% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 4328.234% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 88.539% |
| Denali Therapeutics Inc. | -145.22 Million USD | 385.65% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 345063.161% |
| Veru Inc. | -93.15 Million USD | 545.325% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 1634.766% |
| Cingulate Inc. | -23.53 Million USD | 1862.621% |
| Passage Bio, Inc. | -102.06 Million USD | 506.451% |
| Context Therapeutics Inc. | -23.96 Million USD | 1831.048% |
| Exicure, Inc. | -16.91 Million USD | 2552.595% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 319.584% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 1198.485% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 6474.847% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 324.624% |
| Nuvalent, Inc. | -126.21 Million USD | 428.661% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 4044.899% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 577.482% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 1458.146% |
| OmniAb, Inc. | -50.61 Million USD | 919.518% |
| Anew Medical, Inc. | 1.34 Million USD | -30716.752% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 2685.428% |
| Lipocine Inc. | -16.35 Million USD | 2636.876% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 724.803% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 751.483% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 1083.159% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 964.828% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 2191.836% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 176.609% |
| Ocugen, Inc. | -63.07 Million USD | 757.649% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 533.326% |
| Q32 Bio Inc. | -112.96 Million USD | 467.235% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 2512.936% |
| Alumis Inc. Common Stock | -154.99 Million USD | 367.646% |
| Equillium, Inc. | -13.33 Million USD | 3210.851% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 787.195% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 5293.296% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 2300.557% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 802.129% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 462.213% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 2357.226% |
| Dominari Holdings Inc. | -22.88 Million USD | 1912.918% |
| Edesa Biotech, Inc. | -8.37 Million USD | 5053.564% |
| vTv Therapeutics Inc. | -20.25 Million USD | 2148.553% |
| Bio-Techne Corporation | 168.1 Million USD | -146.77% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 217.821% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -221.942% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 440.495% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 1193.418% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 468.275% |
| Nkarta, Inc. | -117.5 Million USD | 453.046% |
| BioCardia, Inc. | -11.57 Million USD | 3685.101% |
| Iterum Therapeutics plc | -38.37 Million USD | 1181.108% |